The cyclin-dependent kinase 4 (CDK4) amplicon is frequently amplified in numerous human cancers including gliomas. PIKE-A, a proto-oncogene that is one of the important components of the CDK4 amplicon, binds to and enhances the kinase activity of Akt, thereby promoting cancer progression. To define the roles of the PIKE-A/Akt interaction in glioblastoma multiform (GBM) progression, we used biochemical protein/protein interaction (PPI) assays and live cell fluorescence-based protein complementation assays to search for small peptide antagonist from these proteins that were able to block their interaction. Here, we show that disruption of the interaction between PIKE-A and Akt by the small peptides significantly reduces glioblastoma cell proliferation, colony formation, migration and invasion. Disruption of PIKE-A/Akt association potently suppressed GBM cell proliferation and sensitized the cells to two clinical drugs that are currently used to treat GBM. Interestingly, GBM cells containing the CDK4 amplicon were more responsive to the inhibition of the PIKE-A/Akt interaction than GBM cells lacking this amplicon. Taken together, our findings provide proof-of-principle that blocking a PPI that is essential for cancer progression provides a valuable strategy for therapeutic discovery.
INTRODUCTION
Glioblastoma multiform (GBM), the most common type of primary brain tumors, are highly aggressive, infiltrative and destructive. Recently, radiotherapy plus concomitant and adjuvant temozolomide (TMZ) was shown to significantly improve the survival of GBM patients without reducing their quality of life. 1, 2 However, the aggressive nature of glioblastomas renders current treatments, the median survival after treatment is 14 months. Therefore, novel and effective therapeutic interventions for GBM are urgently needed. For this reason, tremendous effort has been spent to identify tumorigenic or tumor-promoting genomic events and molecular pathways that directly drive malignant transformation and tumor progression.
GBM comprehensive genomic profiles mapped by The Cancer Genome Atlas project reveal that one of the most common copynumber alterations in GBM is amplification at chromosome 12q13.3 --14.1. This amplification is also observed in many other human cancers including melanoma, breast cancers and lung cancers. 3 --7 Importantly, glioblastoma patients harboring this amplification had markedly decreased survival. The cyclindependent kinase 4 (CDK4) gene has been postulated as the target of this amplification. CDK4 promotes proliferation by inhibiting the Rb1 tumor suppressor and by sequestering p27Kip1 and p21Cip1, thereby promoting E2F-and Cdk2-dependent cell cycle progression. 8 However, CDK4 overexpression alone does not induce spontaneous tumorigenesis in transgenic animal models, suggesting that CDK4 cooperates with other genetic changes to initiate tumorigenesis. 9 Frequently co-amplified with CDK4 is CENTG1. CENTG1 encodes a GTPase called PIKE, which directly binds and activates PI 3-kinase and Akt. 10 --13 PIKE-A, a member of the PIKE family, is present in various tissues with higher expression levels in the brain, spleen, thymus, small intestine and peripheral blood leukocytes.
14 --16 PIKE-A contains the GTPase, PH, ArfGAP and two Ankyrin repeat domains present in PIKE-L, but lacks the N-terminal proline-rich domain, which binds protein 4.1N, PI 3-kinase and PLC-g1. 10 ,11 PIKE-A directly binds to Akt and upregulates its activity in a GTP-dependent manner, mediating cancer cell invasion. 12, 13 Human cancer cells with PIKE-amplification are more resistant to apoptosis compared with cancer cells with a normal PIKE-A copy number. Overexpression of wild-type PIKE-A has been shown to stimulate Akt activity and inhibit apoptosis, whereas it has been demonstrated that knockdown of PIKE-A diminishes Akt activity and enhances apoptosis. Therefore, PIKE-A amplification promotes cancer cell growth by inhibiting apoptosis through stimulation of Akt. 12, 13 Moreover, PIKE-A acts as a proto-oncogene, promoting cancer cell survival, invasion and transformation through Akt activation. 17 Most recently, an automated network-based approach, which is used for determining candidate oncogenic processes and driver genes, identified new candidate cancer-causing drivers in GBM, including AGAP2/CENTG1, a putative oncogene and an activator of the PI 3-kinase pathway. 18 This approach is based on the hypothesis that cellular networks contain functional modules and that tumors target-specific modules critical to their growth. Thus, CDK4 and CENTG1 might comprise a functionally integrated oncogene DNA cluster that promotes aggressiveness in human cancers by cooperatively targeting the Rb1 and PI3K/AKT pathways. 19 In this report, we demonstrate that disruption of PIKE-A/ Akt protein/protein interaction (PPI) leads to reduction of GBM cell proliferation, survival, migration and invasion. Moreover, peptides that inhibit this protein complex also sensitize GBM cells to two clinical anti-cancer medicines TMZ and Carmustine (BCNU), especially in GBM cells that harbor the CDK4 amplicon. Therefore, our study provides a proof-of-concept that blockade of critical PPIs in GMB can be a therapeutic target for treating these devastating cancers.
RESULTS

PIKE-A interacts with Akt in live cells
We have previously demonstrated that PIKE-A interacts with Akt in human cancer cells, and determined that the N-terminus of PIKE-A and C-terminus of Akt regulate the interaction between these two proteins. 12, 13 A schematic representation of the protein domains of PIKE-A and Akt and their binding motifs are shown in Figure 1a . Upon further mapping analysis, we found that the purified GSTtagged recombinant N-terminal fragment (a.a. 72 --128) of PIKE-A interacted with HA-Akt (Figure 1b) , which was independent with GTP/GDP. 12 To visualize the interaction between these two proteins, we utilized a Venus-based protein complementation assay . In this assay, the N-terminus of the Venus protein is fused to one protein of interest, while the C-terminus of Venus is fused to another protein. If the two proteins bind to each other, the N-Venus and C-Venus proteins will come in close proximity allowing the Venus protein to reconstitute and yield a fluorescent signal after excitation. As 14-3-3 often exists as dimmers, we used a 14-3-3z protein pair as a positive control. As expected, co-transfection of N-Venus-14-3-3z and C-Venus-14-3-3z resulted in a strong Venus signal, thereby validating this assay. To investigate whether the PIKE-A/Akt interaction occurred in cells, we sub cloned PIKE-A and Akt into pDEST26-C-Venus and pSCM167-N-Venus 20 vectors, respectively, and co-transfected these vectors into the LN229 GBM cell line. Similar to the 14-3-3z pair, co-expression of PIKE-A and Akt resulted in a robust Venus signal. In contrast, co-transfection of C-Venus-PIKE-A and the empty N-Venus vector or C-Venus-Akt and the empty C-Venus vector did not yield significant Venus signals (Figure 1c ). Quantitative analysis of the resulting Venus signals is summarized in Figure 1d . Taken together, these results demonstrate that PIKE-A and Akt interact with each other in live LN229 cells.
Synthetic peptides (sp) derived from the binding motifs of PIKE-A and Akt block their interaction Although the whole protein X-ray structure of PIKE-A is not available yet, the three-dimensional structures of its GTPase domain and PH domain have been elucidated. 21, 22 Molecular modeling of the N-terminus of PIKE-A (a.a. 1 --128) predicts the protein folding to include several b-strands, a a-helix and a loop (Figure 2a) . Based on the predicted structure, we synthesized three peptides with 19 to 27 amino-acid residues (PP1 to PP3). To investigate whether these peptides could disrupt the interaction between PIKE-A and Akt, we conducted an in vitro binding assay using purified recombinant GST-PIKE-A protein and HA-Akt, which Disrupting PIKE-A/Akt interaction suppresses glioma Q Qi et al was isolated from transfected HEK293 cells. Introduction of PP1 or PP2 peptides into the binding solution completely disrupted the association between PIKE-A and Akt at both 10 and 50 mM concentrations (Figure 2b) .
The three-dimensional structure of Akt has been previously reported before. 23 As we have previously demonstrated that the C-terminus of Akt is required for its interaction with PIKE-A, we designed several small peptides (AP1 --AP3) based on the C-terminal regulatory domain structure, which contains a-helices and a loop structure (Figure 2c) . Two of the small peptides, AP1 and AP3, robustly abolished the binding between PIKE-A and Akt, whereas AP2 enhanced the association between these two proteins in a dose-dependent manner (Figure 2d ). To measure the affinity of interaction between PIKE-A and Akt, we examined the effect of various peptides on the interaction of the purified full-length PIKE-A and Akt in an in vitro binding assay. We found that PP1, PP2, AP1 and AP2 suppressed the interaction between PIKE-A and Akt in a concentration-dependent manner, with IC50 Figure 1 . AP1 and AP3 inhibited the interaction of PIKE-A and Akt in a dose-dependent manner. (e) PP1, PP2 and AP1 suppress the purified recombinant PIKE-A and Akt in a concentration-dependent manner. In vitro binding assay: 0.5 mg of purified Akt were incubated with glutathione bead-associated GST-PIKE-A for over night in the presence of indicated concentrations of peptides. The glutathione bead-associated proteins were resolved on 10% SDS --PAGE and analyzed by immunoblotting with Akt antibody. Then the binding index was calculated after normalization with GST-PIKE-A using Image J software. (f ) GST-pull down assay. HEK293 cells were co-transfected with HA-Akt and GST-PIKE-A. After 40 h, the cell lysate was collected and GST-PIKE-A was pulled down with glutathione beads. The associated proteins were analyzed by immunoblotting with an anti-HA antibody. GST-PIKE-A was verified with anti-GST-HRP.
of 0.41, 1.22, 0.87 and 14.06 mM (Figure 2e ). Furthermore, we evaluated the effect of candidate peptides by co-transfecting GST-PIKE-A and HA-Akt into HEK293 cells, followed by a GST pull-down assay performed in the presence of various antagonist peptides. Notably, incubation with PP1 resulted in the dose-dependent disruption of the PIKE-A/Akt interaction, which was also observed to a lesser degree upon incubation with AP1 and AP3. Interestingly, PP2 did not demonstrate an inhibitory effect, even at the 10 mM concentration (Figure 2f ). The discrepant efficacy of ability of the small peptides to inhibit the interaction between PIKE-A and Akt might result from the different folding conformations between full-length PIKE-A and the shorter form of PIKE-A (a.a. 1 --356).
PP1 and AP1 disrupt the PIKE-A/Akt interaction in live cells
To examine dissociating PIKE-A from Akt by the peptides in intact cells, we co-transfected N-Venus-PIKE-A and C-Venus-Akt into LN229 cells along with various GST-tagged antagonist peptides. As shown in Figure 3a , expression of GST-PP1 almost completely Disrupting PIKE-A/Akt interaction suppresses glioma Q Qi et al blocked the binding between PIKE-A and Akt, whereas GST-PP2 and GST-AP1 partially reduced the association (Figure 3a ). Quantitative analysis of the signals indicated that GST-PP1 and GST-AP1 significantly decreased the interaction between PIKE-A and Akt (Figure 3b ). The expression of the transfected peptides, PIKE-A, and Akt were similar between all samples (Figure 3c ). PP1 and AP1 suppress GBM cell survival, viability, migration and invasion To investigate the biological effects of the PIKE-A/Akt interaction in GMB cells with different genetic backgrounds, we utilized the LN229 and LN-Z308 cell lines. Although LN229 cells do not contain the CDK4 amplicon, LN-Z308 cells possess theCDK4 amplicon. 13 After confirming the transfection efficiency (Supplementary Figure 1) , we carried out tumorigenesis assays to evaluate the effect of peptides on GMB cell viability, migration and invasion. Transfection of GST-PP1 substantially reduced the survival of LN-Z308, whereas it had no effect on LN229 cells. Conversely, GST-AP1 significantly decreased the survival of LN229 cells, while it had negligible effect on LN-Z308 cells. The transfection efficiency was confirmed using co-transfected GFP (Supplementary Figure 1) . As expected, GST and GST-PP2 did not have any effect on cell survival, regardless of the cell line (Figure 4a ). Therefore, disrupting the interaction between PIKE-A and Akt strongly induces CDK4 amplicon-containing LN-Z308 cell death. Similar results were obtained from colony formation assays. GST-PP1 and GST-AP1 potently inhibited colony formation in LZ-Z308 cells, while GST-AP1 significantly inhibited colony formation in LN229 cells (Figure 4b ). TMZ and BCNU are two anti-cancer drugs that are used in the clinic for treatment of GBM. To test whether disrupting the PIKE-A/Akt interaction will further enhance the anti-cancer effects of these two drugs, we transfected LN229 and LN-Z308 cells with the short antagonist peptides and incubated the cells in the presence of 25 mM of TMZ or 50-mM BCNU. In LN229 cells, BCNU treatment reduced cell viability regardless of peptide transfection. However, in TMZ-treated cells, the PP1 peptide markedly reduced cell viability compared with the GST control and PP2 peptide. Although, TMZ treatment resulted in a modest effect in repressing LN229 cell viability compared with vehicle ( Figure 4c ). In LN-Z308 cells, transfection of PP1 or AP1 alone was sufficient to diminish cell viability. Interestingly, treatment with BCNU or TMZ did not prominently enhance effect of these peptides on cell viability (Figure 4d) .
To examine the effect of disruption of the PIKE-A/Akt interaction on GBM on cell migration, we transfected the antagonist peptides into LN229 and LN-Z308 cells followed by cell migration analysis. The results demonstrated that none of these peptides significantly reduced the migration of LN229 cells. In contrast, both PP1 and AP1, but not PP2, potently reduced the migration of LN-Z308 cells as compared with control GST (Figure 4e ). Moreover, we also investigated the effect of the peptides on GBM cell invasion. To this end, we co-transfected GST-tagged peptides with GFP into the GBM cells and quantitatively analyzed the invasion of GFPpositive cells. Both PP1 and AP1, but not PP2, robustly repressed the invasion of both LN229 and LN-Z308 cells as compared with control GST (Figure 4f ). Collectively, these data suggest that inhibition of the PIKE-A/Akt PPI by the PP1 and AP1 peptides might suppress GBM cancer progression. Furthermore, we found that these peptides can also enhance the anti-cancer activities of TMZ and BCNU in CDK4 amplicon-containing GBM cells.
Design of smaller synthetic peptides disrupting the PIKE-A/Akt interaction The PP1, PP2 and AP1 peptides contain 19, 19 and 21 amino-acid residues, respectively. Owing to their relatively large size, they cannot penetrate the cell plasma membrane and enter live cells by diffusion. In order to develop smaller peptides that are able to enter live cells and disrupt the PIKE-A/Akt interaction, we synthesized three shorter peptides for each of the above peptides. The sequence of each of the short peptides is listed in Figure 5a . The results from an in vitro binding assay revealed that the sp2 peptide (PELRLGVL) from PP1, sp4 peptide (DARSG) and sp6 peptide (TGSYQ) from PP2, and sp9 peptide (LKKDPK) from AP1 decreased the interaction between a fragment of PIKE-A (1 --356 a.a.) and Akt (Figures 5a and b) . Quantitative analysis of several independent assays indicated that at 50 mM sp2, sp4 and sp6 significantly disrupt the interaction between PIKE-A and Akt. Notably, at 10 mM, PP2 and smaller peptides derived from PP2, sp4 and sp6, failed to block the PIKE-A/Akt interaction, but at 50 mM, sp4 and sp6 peptides were able to disrupt the interaction between PIKE-A and Akt (Figure 5c ). To further investigate the inhibitory effects of the shorter peptides, we co-transfected GST-PIKE-A fulllength and HA-Akt and performed GST pull-down assay. The results from these assays indicate that sp2, sp4 and sp6 exhibit a dose-dependent reduction of the binding of PIKE-A to Akt; in contrast, none of the short peptides from the Akt C-terminal peptide, AP1, exhibited an inhibitory effect (Figure 5d ). As expected, the longer peptide PP1 displayed a slightly more potent inhibitory effect on the PIKE-A/Akt interaction than sp2, wheras the sp5 peptide had no effect at all (Figure 5e ). To assess whether the small peptide sp2 could disrupt the PIKE-A/Akt complex in a time dependent manner, we co-transfected HEK293 cells with GST-PIKE-A and HA-Akt, then treated the cells with 50-mM sp2 for various time points and conducted a GST pull-down assay. The sp2 peptide inhibited PIKE-A binding to Akt at 4 h. The inhibition increased in a time-dependent manner and peaked at 16 h. At 24 h, the peptide lost its suppressive activity (Figure 5f ). Presumably, this peptide was degraded after 24-h incubation in cell culture medium. sp2 inhibits GBM cell viability, migration, invasion and colony formation We next sought to determine the effect of these smaller peptides on GBM cell survival, migration, invasion and colony formation. To this end, we treated LN229 and LN-Z308 cells with 50 mM of the various small antagonistic peptides. The results from an MTT assay demonstrated that sp2 and sp6 selectively decreased LN-Z308 cell viability, whereas sp4 had no effect. Interestingly, the reduction in viability caused by the sp2 and sp6 peptides was only observed in LN-Z308 cells, not in LN229 cells (Figure 6a) . Similar results were seen in cell migration assays (Figure 6b) . Conversely, sp2 strongly inhibited the invasive activity of both LN229 and LN-Z308 cells. Notably, sp4 and sp6 did not significantly affect in invasive activity of either cell line (Figure 6c ). To determine whether the sp2 peptide acted additively or synergistically with commonly used anti-cancer drugs on GBM cell viability, we treated LN229 and LN-Z308 cells with TMZ (25 mM) or BCNU (50 mM) in the presence of various concentration of sp2. The results from these assays revealed a suppressive activity of sp2 on LN-Z308 cell viability, which occurred in a dose-dependent manner. However, its activity towards LN229 cells was not as evident as in LN-Z308 cells. TMZ potently decreased both LN-Z308 and LN229 cell viability and co-treatment with the sp2 peptide elicited an additive effect in LN-Z308 cells. The inhibitory trend was similar in LN229 cells. Similar results on cell viability were observed for co-treatment of sp2 peptide and BCNU (Figure 6d) . To assess the effect of sp2 on the colony formation inhibitory effects of TMZ and BCNU, we treated GBM cells lines with TMZ or BCNU in the presence of various doses of sp2. The results from the colony formation assays revealed that TMZ and BCNU decreased the colony numbers of both cells. This effect was substantially increased by co-treatment with 50-mM sp2 in LN-Z308 cells. The additive trend also applied in LN229 cells (Figure 6e) . Furthermore, similar observations were observed in TP366 cells, another CDK4 amplicon-expressing GBM cell line sp2 inhibits the endogenous interaction between PIKE-A and Akt Our studies indicate that sp2 strongly inhibits LN-Z308 cell viability, migration, invasion and colony formation. This suppressive activity may occur through the ability of sp2 to disrupt the PIKE-A/Akt interaction, leading to blockade of signaling cascades /well) were seeded in six-well plates. Peptides and vector plasmids were transfected with FuGENE HD transfection reagent. After 40 h, cell migration was determined using a wound-healing assay. Mention the quantification/statistics used (f ). Cells (1 Â 10 5 /well) were seeded in six-well plates. Peptides, vector plasmids and GFP expression plasmids were transfected with FuGENE HD transfection reagent. After 40 h, cell invasion was determined using a transwell invasion assay as described. Data represent mean ± s.d. (*Po0.05, **Po0.01).
Disrupting PIKE-A/Akt interaction suppresses glioma Q Qi et al downstream of Akt. To investigate this possibility, we treated LN-Z308 cells with different concentrations of sp2 peptide, or sp4 peptide as a control. Co-immunoprecipitate assays demonstrated that sp2 disrupts the association between endogenous PIKE-A/Akt in a dose-dependent manner, whereas SP4 did not affect the PIKE-A/Akt interaction (Figure 7a) . Our previous studies demonstrate that PIKE-A is required for Akt activation. 12, 24 Immunoblotting analysis of peptide-treated cell lysates indicates that both Akt (e) A GST-pull down assay as described in Figure 2 demonstrated that both PP1 and SP2 inhibited the binding of PIKE-A and Akt. (f ) Timecourse study of the effect of sp2 on the interaction of PIKE-A and Akt. HEK293 cells were co-tranfected with HA-Akt and GST-PIKE-A, followed by treatment with sp2 (50 mM) for the indicated times. GST-PIKE-A was pulled down with glutathione beads. The associated proteins were analyzed with an anti-HA antibody. Treatment with sp2 for 16 h significantly decreased the interaction of PIKE-A and Akt.
T308 and S473 phosphorylation were diminished by sp2 peptide treatment in a dose-dependent manner, whereas SP4 had no effect on Akt phosphorylation. These results support the hypothesis that abolishment of the PIKE-A/Akt association leads to a reduction in Akt activity. In agreement with these observations, the well-established downstream effectors of Akt including mTOR, rpS6 and GSK3a exhibited the similar decreased phosphorylation patterns after treatment with sp2 (Figure 7b) . Collectively, these results indicate that disruption of the PIKE-A/Akt interaction by the sp2 peptide decreases Akt activation and thus signaling cascades downstream of Akt.
DISCUSSION
The key finding of this report is that disruption of the PIKE-A/Akt interaction in GBM cells by small antagonist peptides decreases cell viability, suppresses cell migration and invasion, diminishes colony formation and additively enhances the effects of the commonly used chemotherapeutic drugs. Moreover, we found that CDK4 amplicon-containing GBM cells are more sensitive to the effects of the small peptides than the GBM cells without the CDK4 amplicon. Our previous studies established that a pronounced overexpression of PIKE-A in a variety of human tumors and that the activation of Akt by PIKE-A contributed to the progression of these tumors. 12, 13, 17 In the current report, we provide compelling evidence to demonstrate that inhibition of the interaction between PIKE-A and Akt substantially blocks GBM cell viability, migration, invasion and colony formation. The small peptides we identified from the N-terminus of PIKE-A provided us with a powerful tool to specifically interrogate the biological actions of the PIKE-A/Akt interaction in cancer cell development. The small peptide sp2 contains only 8 amino acids with molecular /well) were seeded in six-well plates, cell migration was studied using a healing assay in the presence of the indicated peptides. After 10 h, the migration image was collected and analyzed by Image J software. (c) Cell invasion assay. Cells (1 Â 10 5 /well) were seeded in six-well plates followed by treatment with the indicated peptides 16 h. Cell invasion was determined using a transwell invasion assay described. (d) The effect of sp2 alone or in combination with BCNU or TMZ, on cell viability. Cells (5 Â 10 3 /well) were seeded in 96-well plates followed by treatment with sp2 in the absence or presence of BCNU/TMZ at the indicated concentrations for 16 h. An MTT assay was performed to determine cell viability. (e) The effect of sp2 alone or in combination with BCNU or TMZ on colony formation. Combined treatment of sp2 enhanced the inhibitory effects of BCNU/TMZ on LN-Z308 colony formation. Data represent mean±s.d. (*Po0.05, **Po0.01).
weight about 878.1 U. This peptide effectively disrupts the endogenous PIKE-A/Akt associate in GBM cells, resulting in the suppression of Akt signaling cascades. Our results indicate that sp2 might be able to penetrate intact cells and exert its inhibitory effects by blocking the interaction between PIKE-A and Akt.
PI 3-kinase/Akt signaling cascade is commonly activated in many human malignancies, including GBM. This pathway can be activated via numerous upstream alterations including genomic amplification of epidermal growth factor receptor, PTEN deletion or PIK3CA mutations. Akt promotes cell survival by inhibiting proteins that mediate apoptosis and by upregulating proteins that inhibit apoptosis. For example, Akt phosphorylates the pro-apoptotic Bcl-2 family member BAD, 25, 26 caspase-9 27 and apoptosis signal-regulating kinase 1 (Ask1) 28 and inhibits their pro-apoptotic functions. In addition, Akt is a crucial factor in regulating diverse tumorigenic activities such as angiogenesis and tissue invasion/metastasis. 29 Inhibition of PI 3-kinase/Akt signaling has been well characterized as a therapeutic target for treating various human cancers including GBM. Nonetheless, Akt is essential for a variety of molecular and cellular processes in normal cells. Direct blockade of Akt might disturb numerous ordinary cellular processes and yield undesirable side effects. The feasibility of targeting PPIs for functional studies has been well established. As an increasing number of protein complexes and interconnected protein networks are revealed by a variety of experimental approaches, general principles underlying PPIs and their roles in controlling cellular processes have emerged. It appears that a general mode of PPI is mediated by a contiguous stretch of amino-acid sequences or a defined structure to form protein domains or modules within individual proteins. 30 These protein domains or modules offer tractable molecular targets for tool design and mechanistic interventions. For example, molecular studies have mapped the MDM2/p53 interaction interfaces to a 15-residue a-helical region of p53, which has been extensively targeted for defining the oncogenic properties of MDM2 in a number of tumors, including GBM. Thus, using a peptide disruption approach is expected to identify critical PPIs in oncogenic signaling pathways in GBM. The exciting data presented in this report provide a proof-of-concept that targeting a crucial PPI in GBM may not only address its biological roles in cancer progression but also establish a drug-screening target for cancer treatment. Here, we provide an alternative approach to target Akt activation by disrupting the PIKE-A/Akt interaction. Conceivably, targeting this PPI, instead of inhibiting Akt itself directly, might result in less severe side effects. The small peptides identified in this study could be used as a template for in silico screening to search for small molecules that may share a similar three-dimensional structure as the 8-mer peptide, and thus specifically abolish the interaction between PIKE-A and Akt. Conversely, the fluorescent live-cell image analysis could be used as a screening tool to quantitatively screen small molecules to inhibit the PIKE-A/Akt interaction. The compounds that are discovered through these studies may serve as positive hits for further drug development for the treatment of cancer.
In the present study, we have found that GBM cells that harbor the CDK4 amplicon are more responsive to dissociation of the PIKE-A/Akt interaction than GBM cells without the CDK4 amplicon (Figures 4 and 6 ). CDK4 amplicon contains CDK4, CENTG1, SAS and OS9 genes. This amplicon is frequently amplified in numerous human cancers including sarcoma, brain tumors, lung cancer, melanoma and so on. 3 --7 It often co-amplifies with the oncogene MDM2. Presumably, these oncogenes coordinate with each other to upregulate proliferative signals and enhance cancer cell growth and transformation. In addition, Cdks have essential roles in regulating cell proliferation and tumorigenesis. During the G 1 phase, Rb proteins are inactivated by sequential phosphorylation mediated by various Cdks, mainly the D-type cyclin-dependent Cdk4 and Cdk6 and the E-type cyclin-dependent Cdk2. 31 Inactivation of Rb proteins results in the release and/or activation of proteins, including E2F, required for cell cycle progression. Conceivably, GBM cells with the CDK4 amplicon might be more dependent on CDK4 and PIKE-A proteins to gain extra proliferation advantage. The concomitant contribution of CDK4 and PIKE-A/Akt signaling to tumor progression might provide a selective target for future personalized anti-cancer drug therapy. Taken together, our study demonstrates the interrogation of a PPI in GBM using small peptides can provide the biological roles of PPIs in cancer progression, which lays down the groundwork for subsequent investigation of the PPI's functions in tumorigenesis in animal models. This knowledge paves the way for targeting the specific PPI for further drug screening and development.
MATERIALS AND METHODS
Cell lines and reagents
HEK293 cells and the human glioblastoma, LN229, LN-Z308 and TP366 cells were maintained in DMEM with 10% FBS and 1X pen/strep/glutamine supplemented with various selection antibiotics at 37 1C in a 5% CO 2 atmosphere in a humidified incubator. Anti-HA-HRP and anti-GST-HRP antibodies were from Sigma (St Louis, MO, USA). All other antibodies were from Cell Signaling (Beverly, MA, USA). The Horseradish peroxidase linked IgG secondary antibodies were purchased from GE healthcare (Sweden, UK). Protein A/G-conjugated agarose beads were from Calbiochem (Darmstadt, Germany). Glutathione Sepharose 4B was supplied by Amersham Pharmacia (Sweden, UK). All of the chemicals not included above were from Sigma.
Plasmid construction
All plasmids were constructed using Gateway technology (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocols. The pDEST26-C-Venus (Invitrogen) and pSCM167-N-Venus 20 vectors were used as vectors. Insertions were amplified by PCR and then inserted into the pDONR201 vector using a BP reaction. An LR reaction was used to transfer the desired DNA into the appropriate destination vectors. All constructs were verified by sequencing analysis.
Cell viability assay
Cells were seeded in 96-well plates at a density of 3000 cells per well. The next day, the medium was replaced with fresh medium containing drugs/ peptides or vehicle controls. Cell were incubate at 37 1C for indicated times. The cell proliferation was monitored by an MTT/BrdU incorporation assay according to the manufacturer's protocols.
Cell migration and invasion assays Cells (300 000 per well) were seeded in a six-well plate. Approximately 24 h later, when the cells were 100% confluent, the monolayer was scratched using a 200-ml pipette tip and washed once to remove nonadherent cells. New medium containing the antagonist peptides or DMSO was added (0 h) and allowed to incubate for 10 h. The cells were observed using a light microscope. Inhibition of migration was assessed using Image J software, available from the National Institutes of Health Web site (http://rsb.info.nih.gov/ij/). The percent of wound healed was calculated using the formula: 100À[(final area/initial area) Â 100%]. For cell invasion assay, invasion of cells through Matrigel was determined using a transwell system (10 mm diameter, 8 mm pore size with polycarbonate membrane; Corning Costar) as described previously. 17 Colony formation assay A base 0.6% agar gel with 10% FBS in DMEM was prepared and added to the wells of a six-well culture dish. Cells were plated at a density of 50 000 cells per well on top of the base agar for anchorage-independent growth analysis in 0.4% agar gel with 10% FBS in DMEM supplemented with drugs/peptides or vehicle. The cells were maintained at 37 1C and allowed to grow for 2 weeks. The colonies were stained using MTT dye (100 ml per well). The colonies were scored and the numbers were normalized as the percentage of colonies formed in vehicle.
Co-immunoprecipitation and in vitro binding assays
Experimental procedures for the co-immunoprecipitation and in vitro binding assays have been previously described. 32 
ELISA protein interaction assay
Reacti-Bind glutathione-coated ELISA plates (Pierce, Rockford, IL, USA) were treated with purified GST -PIKE-A (a.a. 1 --356) for 16 h at 4 1C and then washed three times with wash buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Tween-20). Peptides were add to the wells (20 ml/well) and incubated for 3 h at room temperature, followed by incubation with HAAkt-containing cytosolic extracts from transfected HEK293 cells diluted in wash buffer for 4 h at room temperature. Akt binding was detected with biotin-conjugated Akt antibody and streptavidin-horseradish peroxidase (0.5 mg/ml; Jackson ImmunoResearch, West Grove, PA, USA). Color development was stopped after 1 --2 min by the addition of 100 ml of 0.2-M citric acid/well. OD405 --490 was quantitated on a 96-well plate reader (Synergy 2, Bioteck, Winooski, VT, USA).
Statistical analysis
Data are presented as mean ± s.d. of three or four independent experiments. Statistical evaluation was carried out using the Student's t-test. Data were considered statistically significant when Po0.05. All statistical analyses were performed using Prism GraphPad software (La Jolla, CA, USA).
